AzTrials
AzTrials

Knee Pain ChronicTKANCT04817969

Persona Ti-Nidium Post-Market Clinical Follow-up

A study testing Zimmer Biomet Persona Ti-Nidium Total Knee System in people with Knee Pain Chronic and Osteoarthritis, run by Zimmer Biomet at 7 sites in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

The main objectives of this study are to evaluate overall clinical performance and safety of the Persona Ti-Nidium implant in total knee arthroplasty. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Zimmer Biomet Persona Ti-Nidium Total Knee System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
240 participants
Where
7 sitesUnited States
Study dates
1 Jun 2021to May 2034
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient is of legal age and skeletally mature
  • Patient is willing and able to provide written Informed Consent by signing and dating the IRB-approved Informed Consent document
  • Patient is willing and able to complete scheduled follow-up evaluations as defined in the study protocol
  • Patient qualifies for total knee arthroplasty based upon physical exam and medical history, and meets the approved indications for use of the Persona Ti-Nidium Knee System and Vivacit-E polyethylene articulating surface
  • Independent of study participation, patient is a candidate for the commercially available Persona Ti-Nidium Knee and Vivacit-E polyethylene articulating surface, implanted in accordance with product labeling
  • Study Device Inclusion Criteria:
Show all 11Show fewer
  • The Persona Ti-Nidium Total Knee is intended for patients with severe pain and disability due to the following:
  • Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis.
  • Collagen disorders, and/or avascular necrosis of the femoral condyle.
  • Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.
  • Moderate valgus, varus, or flexion deformities.

Who cannot join

  • Patient is unwilling to sign the Informed Consent
  • Patient is currently participating in any other surgical intervention or pain management study
  • Patient is pregnant or considered a member of a protected (vulnerable) population whose inclusion in the study is inappropriate (e.g. prisoner, mentally incompetent)
  • Patient has a mental or neurologic condition who is unwilling or incapable of following postoperative care instructions
  • Patient has a condition which would, in the judgement of the Investigator, place the patient at undue risk or interfere with the conduct of the study
  • Patient is institutionalized or is a known drug abuser, a known alcoholic or cannot understand the requirements of study participation
Show all 16Show fewer
  • Study Device Exclusion Criteria
  • Previous history of infection in the affected joint and/or other local/systematic infection that may affect the prosthetic joint
  • Insufficient bone stock on femoral or tibial surfaces
  • Skeletal immaturity
  • Neuropathic arthropathy
  • Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb
  • A stable, painless arthrodesis in a satisfactory functional position
  • Severe instability secondary to the absence of collateral ligament integrity
  • Rheumatoid arthritis (RA) accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin
  • The kinematic alignment surgical technique is contraindicated for patients with greater than 5° valgus deformity with medial collateral ligament (MCL) insufficiency

Trial locations and contacts

7 sites in 1 country.

7 sites in 1 country

United States7 sites
  • New Mexico Orthopaedic Associates

    Albuquerque, New Mexico, 87110

  • Duke University

    Durham, North Carolina, 27708

  • MedStar Health Research Institute

    Hyattsville, Maryland, 20782

  • Mississippi Sports Medicine and Orthopaedic Center

    Jackson, Mississippi, 39202

  • Denver Hip & Knee, Inc.

    Parker, Colorado, 80134

  • Rothman Orthopaedic Institute

    Philadelphia, Pennsylvania, 19107

  • Monument Health Rapid City Hospital, Inc.

    Rapid City, South Dakota, 57701

Other trials in United States

About this study

Official title: Persona® Ti-Nidium® Personalized Total Knee System A Post-Market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data Using the Persona Ti-Nidium Total Knee System and Instrumentation

The main objectives of this study are to evaluate overall clinical performance and safety of the Persona Ti-Nidium implant in total knee arthroplasty.

Read the detailed description

The study design is a prospective, multicenter data collection model of the 510(k) cleared Persona Ti-Nidium Total Knee System. The study will require each site to obtain institutional review board (IRB) approval prior to study enrollment. All potential study subjects will be required to participate in the Informed Consent Process.

All study subjects will undergo preoperative clinical evaluations prior to their total knee arthroplasty. Investigators will collect clinical data for a required 10 years. Follow-up clinical visits include Early Post-op, 6 months, 1 year, 2, 3, 5, 7 and 10 years post-operatively.

The objective of this study is to evaluate clinical performance, benefits and safety of the Persona Ti-Nidium implant in total knee arthroplasty.

Specific assessments include:

  1. Confirming the long-term safety, performance and clinical benefits of the Persona Ti-Nidium total knee system and instrumentation in primary and revision TKA.
  2. Verifying that, under normal use, the performance and clinical benefits of this device and its instrumentation conform to those intended by the manufacturer by recording patient-reported clinical outcomes measures (PROMs) and radiographic outcomes (if available).
Being tested
Zimmer Biomet Persona Ti-Nidium Total Knee System
Keywords
Osteoarthritis, Rheumatoid Arthritis, Total Knee Arthroplasty
Medical subject headings
Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Osteonecrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Zimmer Biomet Persona Ti-Nidium Total Knee SystemDevice

    Primary Knee Total Arthroplasty

Study groups in NCT04817969
Study groupRoleWhat they receive
Persona Ti-NidiumOtherPrimary total knee arthroplasty subjects that receive the Zimmer Biomet Persona Ti-Nidium Total Knee System
Receives: Device: Zimmer Biomet Persona Ti-Nidium Total Knee System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Oxford Knee Score (OKS)

    A patient reported functional outcome score for knee arthroplasty. This score ranges from 0-48, with higher scores indicating a better outcome.

    Measured: 10 years

Secondary outcomes (2)
  1. Knee Society Score (KSS) Expectations (pre and post op)

    This is a 3 question form regarding a patient's expectations of the total knee replacement. The pre-op form assesses the patient's expectations of the knee replacement, and the post-op form addresses how the replacement is meeting said expectations. The score ranges from 3-15, with higher scores indicating a better outcome.

    Measured: 10 years

  2. EuroQol Five Dimension Five Level (EQ-5D-5L) Outcomes Measure

    A questionnaire completed by the patient and assesses his/her general health status. This score ranges from -0.573 to 1, with higher recorded scores indicating better overall health.

    Measured: 10 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Mar 2021
  2. Study start1 Jun 2021
  3. Primary completionMay 2034 (estimated)
  4. Study completionMay 2034 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
240 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04817969
Sponsor's protocol ID
CMG2020-05K
Acronym
TKA
Status last verified
Oct 2025
First submitted
23 Mar 2021
Last updated
22 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in